Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Germani MM, Vetere G, Giordano M, Ciracì P, Capone I, Tamborini E, Conca E, Busico A, Pietrantonio F, Piva VM, Boccaccino A, Simionato F, Bortolot M, Manca P, Lonardi S, Conca V, Borelli B, Carullo M, Del Re M, Fontanini G, Rossini D, Cremolini C. Germani MM, et al. Among authors: busico a. Front Oncol. 2024 Feb 9;13:1307545. doi: 10.3389/fonc.2023.1307545. eCollection 2023. Front Oncol. 2024. PMID: 38406172 Free PMC article.
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.
Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, Cavalieri S, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M. Vallacchi V, et al. Among authors: busico a. J Immunother Cancer. 2024 Jan 4;12(1):e007612. doi: 10.1136/jitc-2023-007612. J Immunother Cancer. 2024. PMID: 38177075 Free PMC article.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Pusceddu S, et al. Among authors: busico a. J Hematol Oncol. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9. J Hematol Oncol. 2023. PMID: 38098114 Free PMC article. Clinical Trial.
Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors.
Minna E, Devecchi A, Pistore F, Paolini B, Mauro G, Penso DA, Pagliardini S, Busico A, Pruneri G, De Cecco L, Borrello MG, Sensi M, Greco A. Minna E, et al. Among authors: busico a. Front Endocrinol (Lausanne). 2023 Oct 5;14:1267499. doi: 10.3389/fendo.2023.1267499. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37867524 Free PMC article.
Can we define breast cancer HER2 status by liquid biopsy?
Di Cosimo S, De Marco C, Silvestri M, Busico A, Vingiani A, Pruneri G, Cappelletti V. Di Cosimo S, et al. Among authors: busico a. Int Rev Cell Mol Biol. 2023;381:23-56. doi: 10.1016/bs.ircmb.2023.07.003. Epub 2023 Sep 4. Int Rev Cell Mol Biol. 2023. PMID: 37739483 Review.
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei.
Kusamura S, Busico A, Conca E, Capone I, Agnelli L, Lorenzini D, Brich S, Angelini M, Volpi CC, Trupia DV, Lagano V, Torelli T, Gloghini A, Baratti D, Guaglio M, Milione M, Deraco M, Perrone F. Kusamura S, et al. Among authors: busico a. Biomedicines. 2023 Jul 20;11(7):2049. doi: 10.3390/biomedicines11072049. Biomedicines. 2023. PMID: 37509688 Free PMC article.
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care.
Vingiani A, Agnelli L, Duca M, Lorenzini D, Damian S, Proto C, Niger M, Nichetti F, Tamborini E, Perrone F, Piccolo A, Manoukian S, Azzollini J, Brambilla M, Colombo E, Lopez S, Vernieri C, Marra F, Conca E, Busico A, Capone I, Bozzi F, Angelini M, Devecchi A, Salvatori R, De Micheli V, Baggi A, Pasini S, Jommi C, Ladisa V, Apolone G, De Braud F, Pruneri G. Vingiani A, et al. Among authors: busico a. JCO Precis Oncol. 2023 Jul;7:e2300067. doi: 10.1200/PO.23.00067. JCO Precis Oncol. 2023. PMID: 37487147 Free PMC article.
Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruneri G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, Milione M. Centonze G, et al. Among authors: busico a. Neuroendocrinology. 2023;113(4):457-469. doi: 10.1159/000528186. Epub 2022 Nov 23. Neuroendocrinology. 2023. PMID: 36417840 Free article.
53 results